Halozyme Therapeutics Inc (HALO)

[maumar]

The PE is “low” because of the patent cliffs and the lack of new deals, which make revenue growth durability impossible. I think the only solution would be a bold new acquisition but that I suspect could only happen in a couple of years if they stop the stock buybacks and sell some shares to raise more funds.